Abstract 151: Effects of Atorvastatin on Mortality and Inflammatory Responses to Severe Hemorrhagic Shock in Rats
Recent studies reported that the treatment with statin inhibited the elevation of inflammatory cytokines such as TNF-alpha and IL-1 beta and inhibited the release of NO in vitro and in vivo. Moreover, several papers reported that statin has the beneficial effects in patients with cardiogenic shock. However, there are few studies about the effects of statin during severe hemorrhagic shock. To evaluate the effects of statin in an animal model of severe hemorrhagic shock. Atorvastatin was used as the statin agents. Twenty-eight male Sprague Dawley rats were used. Animals were randomly assigned to one of two groups: control group, no medication; treatment group, oral administration of atorvastatin (10 mg/kg/day) for 5 days. After then, all animals were anesthetized with pentobarbital ip. Hemorrhagic shock (less than 40mmHg in systolic arterial pressure) was induced with removing of blood and was maintained for 40 mins. After 40 mins of shock, a half dose of removing blood and the same dose of Lactated Ringer's solution were administered. There were no other therapies before, during or after hemorrhagic shock. Hemodynamics and arterial blood gases were recorded, and mortality were calculated for the 8-hr observation period and plasma cytokine (TNF-alpha, Interleukin-6 and IL-1 beta) concentrations were measured at 8-hr after hemorrhagic shock. The mortality rates at 8hrs after hemorrhagic shock were 86% and 43% for control and treatment groups, respectively. Heart rate and blood pressure are maintained significantly higher in the treatment group. The increases of lactate concentrations were less for the treatment group than the control group. The present study showed that oral administration of atorvastatin had the beneficial effects on mortality to severe hemorrhagic shock in rats. These finding suggest that atorvastatin may improve the recovery of hemorrhagic shock.
- © 2010 by American Heart Association, Inc.